Indication

Intermediate Risk MDS Per IPSS-R

1 clinical trial

1 product

Clinical trial

A Phase 2 Open-Label Study to Evaluate Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)

Status: Recruiting, Estimated PCD: 2025-05-01

Product